Olympus Q1 FY2027: Operating profit surges 74% on endoscope demand

Olympus delivered robust Q1 growth across all profit lines. Revenue reached ¥240.4 billion (up 16.4% year on year), operating profit hit ¥28,951 million (up 74.4%), and adjusted operating profit came to ¥30,676 million (up 132.6%). Net income attributable to owners of the parent soared 112.5% to ¥19,102 million, more than doubling from a year earlier.

The revenue expansion was fueled by the mainstay Gastrointestinal Endoscopy Solutions business, where endoscopy systems and devices saw strong demand in North America and Europe. In North America, EDOF-equipped scopes and the EU-ME3 ultrasound system were especially sought after, with supply struggling to keep pace. Europe posted double-digit growth, helped by grant-related projects in Poland and order backlog clearance. The Surgical Interventions business also contributed to top-line growth, led by urology and respiratory devices.

On the profit side, higher sales volume combined with the absence of one-time costs from the quality and regulatory compliance project “Elevate” booked in the prior-year quarter, boosting operating profit. However, a slight deterioration in the cost-of-sales ratio (34.8%, up 0.2 percentage points) due to U.S. tariff hikes partially offset the gains. Currency effects added ¥23,231 million to revenue and ¥4,377 million to operating profit, reflecting the yen’s weakness.

Gastrointestinal Endoscopy Solutions

Revenue in this segment climbed 21.2% to ¥168,448 million, while operating profit surged 113.0% to ¥38,646 million, making it the primary earnings driver. The GI endoscopy field continued to benefit from widespread adoption of EDOF scopes and strong demand for the EU-ME3 system in North America, with robust European sales and double-digit growth in Asia–Oceania. The GI treatment devices sub-segment gained from new product launches such as VIABIL stents in North America, and medical services grew on solid contract renewals. A roughly ¥1.3 billion expense related to the Swan EndoSurgical joint venture was recognized, but the jump in sales and the absence of Elevate costs drove a sharp profit increase.

Surgical Interventions

Revenue here rose 6.7% to ¥71,923 million, but the segment posted an operating loss of ¥2,404 million (versus a ¥1,856 million loss a year ago), highlighting ongoing profitability challenges. Urology products for benign prostatic hyperplasia performed well in Europe and North America, while respiratory devices such as EBUS-TBNA ultrasonic bronchoscopes grew in North America. Surgical endoscopy also increased in Europe. However, shipment suspensions for certain products, sluggish surgical device sales, and higher U.S. tariff costs continued to pressure profits, keeping the segment in the red.

A segment comparison table follows this section.

Total assets at quarter-end stood at ¥1,526,474 million, down ¥10,688 million from the prior fiscal year-end. The acquisition of BioProtect added ¥45,893 million in goodwill and ¥14,216 million in inventories, while cash and equivalents fell ¥69,493 million, largely due to share buybacks. Total liabilities increased by ¥53,450 million to ¥778,572 million, lifted by bond and loan issuance, and the equity attributable to owners of the parent ratio slipped to 49.0% from 52.8%.

Cash flow from operating activities turned positive at ¥14,334 million (from a negative ¥15,203 million a year earlier). Investing activities saw an outflow of ¥64,245 million, reflecting the BioProtect deal and capital expenditure. Financing activities resulted in a net decrease of ¥20,983 million, with ¥77,950 million raised but ¥60,000 million spent on treasury stock and ¥33,033 million in dividends. As a result, cash equivalents dropped ¥69,493 million from the prior year-end to ¥118,545 million.

An annual dividend of ¥30 per share is maintained, with no interim payment and ¥30 planned for the year-end. Additionally, a ¥60 billion share buyback was executed, reinforcing shareholder returns. The buyback sharply increased treasury shares to ¥85,528 million, impacting the capital structure.

Olympus left its full-year consolidated forecasts, announced on May 12, 2026, unchanged. Revenue is projected at ¥1,055.0 billion to ¥1,076.0 billion (up 4.4% to 6.5% from the prior year), operating profit at ¥136.5 billion to ¥155.5 billion (up 40.5% to 60.1%), and net income attributable to owners of the parent at ¥95.5 billion to ¥109.0 billion (up 40.1% to 59.9%). The forecasts factor in assumed exchange rates, U.S. tariff impacts, expanded GI endoscope sales, new product launches, and the consolidation of BioProtect.

Q1 revenue achieved roughly 22–23% of the annual plan, marking a solid start.

A major Q1 development was the acquisition of all shares of Israel-based medical device company BioProtect Ltd., making it a wholly owned subsidiary. The purchase price was approximately $270 million (about ¥43,380 million), resulting in goodwill of ¥41,975 million. BioProtect develops and manufactures a biodegradable balloon spacer that protects the rectum during radiation therapy for prostate cancer, offering synergies with Olympus’s gastrointestinal and urology businesses. The move underscores a strategy to expand the portfolio beyond core endoscopy and deliver value across the entire care pathway.

Acquisition-related costs of ¥484 million (including ¥280 million in Q1) were recognized in SG&A. BioProtect’s revenue contribution is minor for now, but it is seen as a long-term growth driver.

Despite a recovering earnings trajectory, Olympus flags several risk factors:

• Uncertainty over U.S. tariff policy: The company is pursuing refunds under the International Emergency Economic Powers Act, but the amount and timing of any reimbursement are unclear. Tariff costs have already pressured the cost ratio and could continue to weigh on profits depending on trade policy developments.
• Geopolitical risks and currency swings: Middle East tensions and financial market volatility could affect the business environment, with high sensitivity to foreign exchange moves.
• Persistent loss in Surgical Interventions: Shipment suspensions and intensifying competition have delayed profit recovery, making structural reform and new product launches urgent.
• Goodwill impairment risk: The BioProtect deal has sharply increased goodwill; if future business plans fall short, an impairment charge could materialize.

Management acknowledges these risks but expects strong GI endoscope demand and M&A contributions to offset them.

R&D spending remained elevated at ¥25,450 million, representing 10.6% of revenue. Olympus continues to invest in next-generation GI endoscopy technologies and, through Swan EndoSurgical, in endoluminal robotic products. With improved operating cash flow, the company retains capacity for growth investment. Capital expenditure rose 24.3% year on year to ¥16,253 million, directed at expanding production capacity and advancing digitalization.